Physician profile
John H Sullivan
NPI 1285605303
$3,091.99
in general payments reported to CMS, 2019-2025
20 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $374 · 2021: $347 · 2022: $516 · 2023: $334 · 2024: $332 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $474.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $462.17 | 2019-2023 | Bromsite, Xelpros, Cequa |
| Aerie Pharmaceuticals, INC. | $396.73 | 2019-2021 | |
| Alcon Vision LLC | $293.01 | 2022-2025 | Rocklatan, Tryptyr, Clareon |
| Mallinckrodt Hospital Products INC. | $276.41 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $228.01 | 2022-2025 | Vyzulta, Miebo |
| Horizon Therapeutics Plc | $151.59 | 2019-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $113.75 | 2020-2023 | |
| Sight Sciences, INC. | $101.90 | 2019-2024 | Tearcare System, Omni Surgical System |
| Kala Pharmaceuticals, INC. | $101.25 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $91.12 | 2022-2025 | |
| Amgen INC. | $89.44 | 2024-2025 | Tepezza |
| Allergan, INC. | $65.55 | 2020-2021 | |
| Oyster Point Pharma, INC. | $59.92 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $45.49 | 2021-2025 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43.94 | 2022-2025 | |
| Biotissue Holdings INC. | $34.56 | 2021-2022 | |
| Shire North American Group INC | $24.15 | 2019 | |
| Optos, INC. | $19.32 | 2020 | |
| Tearlab Corp | $18.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.